<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN: AND METHODS Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> who received <z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> in a randomized double-blind 6-week study </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Increasing age was related to improvements in <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="23" ids="18059">lipid</z:chebi> assessments </plain></SENT>
<SENT sid="3" pm="."><plain>Men had greater <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> reductions than women, and black/Hispanic patients had less favorable <z:chebi fb="23" ids="18059">lipid</z:chebi> effects than other races/ethnicities </plain></SENT>
<SENT sid="4" pm="."><plain>Increasing baseline <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> was associated with improvements in most <z:chebi fb="23" ids="18059">lipids</z:chebi>; higher baseline non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> with improved <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="4" ids="17855">triglycerides</z:chebi>; higher baseline <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> with greater non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B reductions </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with high baseline non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> or <z:chebi fb="4" ids="17855">triglycerides</z:chebi> less frequently attained <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> targets </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> was inversely related to <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and hs-CRP changes, and higher baseline A1C to smaller <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B reductions </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> was not a significant predictor </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (<z:chebi fb="0" ids="49040">ezetimibe</z:chebi>/<z:chebi fb="0" ids="9150">simvastatin</z:chebi> being more effective than <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>) remained consistent </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of predictive factors should be considered in planning <z:chebi fb="23" ids="18059">lipid</z:chebi>-altering therapy </plain></SENT>
</text></document>